Features of the course and treatment of bronchial asthma combined with arterial hypertension: a review

Abstract

Bronchial asthma (BA) is a serious medical and social problem. Many patients with asthma have various concomitant chronic diseases, among which the pathology of the cardiovascular system occupies an important place. Most often, asthma occurs with arterial hypertension (AH). This concurrence can lead to mutual aggravation and progression of these diseases and may negatively affect the prognosis. Usually, difficulties appear when choosing the most effective therapy for BA along with hypertension. This review aimed to analyse the available publications on the problem of the combination of BA and hypertension. A review of the literature presents the summary, examines data on prevalence and indicates risk factors for the development of hypertension among patients with asthma. The coexistence of these diseases is more typical in older people. The review includes questions regarding the pathophysiology of this comorbidity. The role of impaired gas exchange and hypoxia, endothelial dysfunction, participation of the nitric oxide system and obesity in the development of hypertension in combination with asthma are highlighted. The significance of impaired nonrespiratory lung function is shown, and the inflammation features in this comorbid pathology are indicated, as well as the contribution of numerous genes to the development of asthma along with hypertension. In the literature, 330 common genes have been identified that may be involved in the molecular mechanisms of asthma and hypertension. This study shows the effect of concomitant hypertension on the course, asthma control and quality of life of the patients. In addition, the article shows modern approaches to effective therapy with the main groups of drugs used to treat these diseases. To date, studies have demonstrated the prevalence of the combination of asthma and hypertension in the structure of comorbidity, mutual influence and aggravation of these pathologies. Coexistence of BA and hypertension increases the severity of clinical symptoms. This article shows the important aspects of the treatment of a combination of diseases. The need for a thorough assessment of the safety of pharmacological therapy for BA along with hypertension has been demonstrated.

Keywords

bronchial asthma / arterial hypertension / comorbidity

References

[1] Chuchalin AG, Avdeev SN, Aisanov ZR. Federal guidelines on diagnosis and treatment of bronchial asthma. Pulmonologiya. 2022;32(3):393–447. EDN: HZEHSI doi: 10.18093/0869-0189-2022-32-3-393-447

[2] Чучалин А.Г., Авдеев С.Н., Айсанов З.Р. Бронхиальная астма: федеральные клинические рекомендации по диагностике и лечению // Пульмонология. 2022. Т. 32, № 3. С. 393–447. doi: 10.18093/0869-0189-2022-32-3-393-447

[3] Cardet JC, Bulkhi AA, Lockey RF. Nonrespiratory comorbidities in asthma. J Allergy Clin Immunol Pract. 2021;9(11):3887–3897. doi: 10.1016/j.jaip.2021.08.027

[4] Cardet J.C., Bulkhi A.A., Lockey R.F. Nonrespiratory comorbidities in asthma // J Allergy Clin Immunol Pract. 2021. Vol. 9, N 11. P. 3887–3897. doi: 10.1016/j.jaip.2021.08.027

[5] Kaplan A, Szefler SJ, Halpin DMG. Impact of comorbid conditions on asthmatic adults and children. NPJ Prim Care Respir Med. 2020;30(1):36. doi: 10.1038/s41533-020-00194-9

[6] Kaplan A., Szefler S.J., Halpin D.M.G. Impact of comorbid conditions on asthmatic adults and children // NPJ Prim Care Respir Med. 2020. Vol. 30, N 1. P. 36. doi: 10.1038/s41533-020-00194-9

[7] Tiotiu A, Novakova P, Kowal K, et al. Beta-blockers in asthma: myth and reality. Expert Rev Respir Med. 2019;13(9):815–822. doi: 10.1080/17476348.2019.1649147

[8] Tiotiu A., Novakova P., Kowal K., et al. Beta-blockers in asthma: myth and reality // Expert Rev Respir Med. 2019. Vol. 13, N 9. P. 815–822. doi: 10.1080/17476348.2019.1649147

[9] Tomisa G, Horváth A, Sánta B, et al. Epidemiology of comorbidities and their association with asthma control. Allergy Asthma Clin Immunol. 2021;17(1):95. doi: 10.1186/s13223-021-00598-3

[10] Tomisa G., Horváth A., Sánta B., et al. Epidemiology of comorbidities and their association with asthma control // Allergy Asthma Clin Immunol. 2021. Vol. 17, N 1. P. 95. doi: 10.1186/s13223-021-00598-3

[11] Perelman NL. Impact of comorbid pathology on the quality of life of patients with bronchial asthma. Bulletin Physiology and Pathology of Respiration. 2022;(84):8–14. EDN: VJDAFM doi: 10.36604/1998-5029-2022-84-8-14

[12] Перельман Н.Л. Влияние коморбидной патологии на качество жизни больных бронхиальной астмой // Бюллетень физиологии и патологии дыхания. 2022. № 84. С. 8–14. EDN: VJDAFM doi: 10.36604/1998-5029-2022-84-8-14

[13] Ostroumova OD, Goloborodova IV, Voevodina NYu, et al. Asthma and cardiovascular disease. Consilium Medicum. 2018;20(5):8–16. EDN: XVEWIP doi: 10.26442/2075-1753_2018.5.8-16

[14] Остроумова О.Д., Голобородова И.В., Воеводина Н.Ю., и др. Бронхиальная астма и сердечно-сосудистые заболевания // Consilium Medicum. 2018. Т. 20, № 5. С. 8–16. EDN: XVEWIP doi: 10.26442/2075-1753_2018.5.8-16

[15] Di Raimondo D, Musiari G, Benfante A, et al. Prevalence of arterial hypertension and characteristics of nocturnal blood pressure profile of asthma patients according to therapy and severity of the disease: The BADA Study. Int J Environ Res Public Health. 2020;17(18):6925. doi: 10.3390/ijerph17186925

[16] Di Raimondo D., Musiari G., Benfante A., et al. Prevalence of arterial hypertension and characteristics of nocturnal blood pressure profile of asthma patients according to therapy and severity of the disease: the BADA Study // Int J Environ Res Public Health. 2020. Vol. 17, N 18. P. 6925. doi: 10.3390/ijerph17186925

[17] Smirnova MI, Kurekhyan AS, Gorbunov VM, et al. Prospective follow-up of hypertensive patients with concomitant chronic respiratory diseases in routine practice. Part I. Characterization of adverse events. Cardiovascular Therapy and Prevention. 2022;21(10):6–14. EDN: RCAAZO doi: 10.15829/1728-8800-2022-3383

[18] Смирнова М.И., Курехян А.С., Горбунов В.М., и др. Результаты проспективного наблюдения больных артериальной гипертонией с сопутствующими хроническими болезнями органов дыхания в рутинной практике. Часть I. Характеристика неблагоприятных событий // Кардиоваскулярная терапия и профилактика. 2022. Т. 21, № 10. C. 6–14. EDN: RCAAZO doi: 10.15829/1728-8800-2022-3383

[19] Chazova IE, Zhernakova YuV. Diagnosis and treatment of arterial hypertension [guidelines]. Systemic Hypertension. 2019;16(1):6–31. EDN: AEZOAN doi: 10.26442/2075082X.2019.1.190179

[20] Чазова И.Е., Жернакова Ю.В. Диагностика и лечение артериальной гипертонии // Системные гипертензии. 2019. Т. 16, № 1. С. 6–31. EDN: AEZOAN doi: 10.26442/2075082X.2019.1.190179

[21] Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104. Corrected and republished from: Eur Heart J. 2019 1;40(5):475. doi: 10.1093/eurheartj/ehy339

[22] Williams B., Mancia G., Spiering W., et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension // Eur Heart J. 2018. Vol. 39, N 33. P. 3021–3104. Corrected and republished from: Eur Heart J. 2019. Vol. 40. P. 475. doi: 10.1093/eurheartj/ehy339

[23] Stafeev AN, Logvinenko NI, Melnik AV, Astrakov SV. Bronchial asthma and comorbid diseases. Variants of no synthetases genetic polymorphisms. Modern Problems of Science and Education. 2020;(4):138. EDN: LDHGGL doi: 10.17513/spno.30062

[24] Стафеев А.Н., Логвиненко Н.И., Мельник А.В., Астраков С.В. Бронхиальная астма и коморбидные состояния. Варианты генетических полиморфизмов NO синтетаз // Современные проблемы науки и образования. 2020. № 4. С. 138. EDN: LDHGGL doi: 10.17513/spno.30062

[25] Kurekhyan AS, Smirnova MI, Gorbunov VM, et al. Prevalence and characteristics of blood pressure phenotypes in patients with hypertension and chronic respiratory diseases (study of ambulatory practice data of a cardiologist). Rational Pharmacotherapy in Cardiology. 2020;16(4):542–549. EDN: JSTHHZ doi: 10.20996/1819-6446-2020-08-20

[26] Курехян А.С., Смирнова М.И., Горбунов В.М., и др. Частота и характеристики фенотипов артериального давления у больных с артериальной гипертонией и хроническими болезнями органов дыхания (исследование данных амбулаторной практики кардиолога) // Рациональная фармакотерапия в кардиологии. 2020. Т. 16, № 4. С. 542–549. EDN: JSTHHZ doi: 10.20996/1819-6446-2020-08-20

[27] Partavi MS. Peculiarities of the course and treatment bronchial asthma combined with hypertension [dissertation]. Saint Petersburg; 2022. (In Russ). EDN: QDZUYF

[28] Партави М.С. Особенности течения и лечения бронхиальной астмы, сочетающейся с гипертонической болезнью: дис. …канд. мед. наук. Санкт-Петербург, 2022. EDN: QDZUYF

[29] Antonyuk MV, Gvozdenko TA, Novgorodtseva TP, et al. Features of cytokine profile in patients with bronchial asthma combined with obesity. Medicinskaja immunologija. 2018;20(6):913–920. EDN: YOOZQD doi: 10.15789/1563-0625-2018-6-913-920

[30] Антонюк М.В., Гвозденко Т.А., Новгородцева Т.П., и др. Особенности цитокинового профиля у больных бронхиальной астмой в сочетании с ожирением // Медицинская иммунология. 2018. Т. 20, № 6. С. 913–920. EDN: YOOZQD doi: 10.15789/1563-0625-2018-6-913-920

[31] Chichkova NV, Gasparyan AA, Gitel EP, et al. Asthma in overweight and obese patients: assessment of adipokine profile with different fractions of adipose tissue. Prakticheskaja pul’’monologija. 2019;(3):4–9. EDN: TSHAIX

[32] Чичкова Н.В., Гаспарян А.А., Гитель Е.П., и др. Бронхиальная астма у пациентов с избыточной массой тела и ожирением: оценка адипокинового профиля с учетом разных фракций жировой ткани // Практическая пульмонология. 2019. № 3. С. 4–9. EDN: TSHAIX

[33] Grakhova MA, Troshina IA, Zinkevich ME, Miasnikov ME. Bronchial asthma in obese patients: literature review. Medical Science and Education of Ural. 2021;22(4):172–180. EDN: KJYAEX doi: 10.36361/1814-8999-2021-22-4-172-180

[34] Грахова М.А., Трошина И.А., Зинкевич М.Е., Мясников М.Е. Бронхиальная астма у пациентов с ожирением (обзор литературы) // Медицинская наука и образование Урала. 2021. Т. 22, № 4. С. 172–180. EDN: KJYAEX doi: 10.36361/1814-8999-2021-22-4-172-180

[35] Chuchalin AG. A role of nitric oxide for the modern clinical practice: a scientific report at the 5th Pan-Russian Congress on pulmonary hypertension, December 13, 2017. Russian Pulmonology. 2018;28(4):503–511. EDN: VKAAKU doi: 10.18093/0869-0189-2018-28-4-503-511

[36] Чучалин А.Г. Роль оксида азота в современной клинической практике: научный доклад на V Всероссийском конгрессе «Легочная гипертензия» (13 декабря 2017 г.) // Пульмонология. 2018. Т. 28, № 4. С. 503–509. EDN: VKAAKU doi: 10.18093/0869-0189-2018-28-4-503-511

[37] Kytikova OY, Antonyuk MV, Gvozdenko TA, Novgorodtseva TР. Metabolic aspects of the relationship of asthma and obesity. Obesity and Metabolism. 2018;15(4):9–14. EDN: ZAQJBJ doi: 10.14341/OMET9578

[38] Кытикова О.Ю., Антонюк М.В., Гвозденко Т.А., Новгородцева Т.П. Метаболические аспекты взаимосвязи ожирения и бронхиальной астмы // Ожирение и метаболизм. 2018. Т. 15, № 4. С. 9–14. EDN: ZAQJBJ doi: 10.14341/OMET9578

[39] Miethe S, Karsonova A, Karaulov A, Renz H. Obesity and asthma. J Allergy Clin Immunol. 2020;146(4):685–693. doi: 10.1016/j.jaci.2020.08.011

[40] Miethe S., Karsonova A., Karaulov A., Renz H. Obesity and asthma // J Allergy Clin Immunol. 2020. Vol. 146, N 4. P. 685–693. doi: 10.1016/j.jaci.2020.08.011

[41] Peters U, Dixon AE, Forno E. Obesity and asthma. J Allergy Clin Immunol. 2018;141(4):1169–1179. doi: 10.1016/j.jaci.2018.02.004

[42] Peters U., Dixon A.E., Forno E. Obesity and asthma // J Allergy Clin Immunol. 2018. Vol. 141, N 4. P. 1169–1179. doi: 10.1016/j.jaci.2018.02.004

[43] Kuznetsova LA, Basova NE. The role of arginine and endothelial nitric oxide synthase in the pathogenesis of Covid-19 complicated by metabolic syndrome. Acta Biomedica Scientifica. 2022;7(6): 51–70. EDN: PRBMCN doi: 10.29413/ABS.2022-7.6.6

[44] Кузнецова Л.А., Басова Н.Е. Роль аргинина и эндотелиальной синтазы оксида азота при заболевании метаболическим синдромом и COVID-19 // Acta biomedica scientifica. 2022. Т. 7, № 6. С. 51–70. EDN: PRBMCN doi: 10.29413/ABS.2022-7.6.6

[45] Molostova TN. Hormone-dependent asthma: past and present. Prakticheskaja pul’’monologija. 2020;(3):3–11. EDN: XULGKC

[46] Молостова Т.Н. Гормонозависимая бронхиальная астма: прошлое и настоящее // Практическая пульмонология. 2020. № 3. С. 3–11. EDN: XULGKC

[47] Adasheva TV, Samorukova EI, Dolbin SS, et al. Approaches to treating patients with arterial hypertension and concomitant bronchopulmonary diseases (chronic obstructive pulmonary disease, asthma). Atmosfera. Novosti Kardiologii. 2022;(1):16–23. EDN: WRRUJK doi: 10.24412/2076-4189-2022-12700

[48] Адашева Т.В., Саморукова Е.И., Долбин С.С., и др. Подходы к терапии пациентов с артериальной гипертонией и сопутствующей бронхолегочной патологией (хроническая обструктивная болезнь легких, бронхиальная астма) // Атмосфера. Новости кардиологии. 2022. № 1. С. 16–23. EDN: WRRUJK doi: 10.24412/2076-4189-2022-12700

[49] Zolotareva O, Saik OV, Königs C, et al. Comorbidity of asthma and hypertension may be mediated by shared genetic dysregulation and drug side effects. Sci Rep. 2019;9(1):16302. doi: 10.1038/s41598-019-52762-w

[50] Zolotareva O., Saik O.V., Königs C., et al. Comorbidity of asthma and hypertension may be mediated by shared genetic dysregulation and drug side effects // Sci Rep. 2019. Vol. 9, N 1. P. 16302. doi: 10.1038/s41598-019-52762-w

[51] Saik OV, Demenkov PS, Ivanisenko TV. Search for new candidate genes involved in the comorbidity of asthma and hypertension based on automatic analysis of scientific literature. J Integr Bioinform. 2018;15(4):20180054. doi: 10.1515/jib-2018-0054

[52] Saik O.V., Demenkov P.S., Ivanisenko T.V., et al. Search for new candidate genes involved in the comorbidity of asthma and hypertension based on automatic analysis of scientific literature // J Integr Bioinform. 2018. Vol. 15, N 4. P. 20180054. doi: 10.1515/jib-2018-0054

[53] Goncharova IA, Bragina EY, Zhalsanova IZ, et al. Putative regulatory functions of SNPs associated with bronchial asthma, arterial hypertension and their comorbid phenotype. Vavilovskii Zhurnal Genet Selektsii. 2021;25(8):855–863. doi: 10.18699/VJ21.099

[54] Goncharova I.A., Bragina E.Y., Zhalsanova I.Z., et al. Putative regulatory functions of SNPs associated with bronchial asthma, arterial hypertension and their comorbid phenotype // Vavilovskii Zhurnal Genet Selektsii. 2021. Vol. 25, N 8. P. 855–863. doi: 10.18699/VJ21.099

[55] Bragina EYu, Goncharova IA, Zhalsanova IZh, et al. Genetic comorbidity of hypertension and bronchial asthma. Arterial’naya gipertenziya. 2022;28(1):87–95. EDN: QXDOMY doi: 10.18705/1607-419X-2022-28-1-87-95

[56] Брагина Е.Ю., Гончарова И.А., Жалсанова И.Ж., и др. Генетическая коморбидность гипертонической болезни и бронхиальной астмы // Артериальная гипертензия. 2022. Т. 28, № 1. С. 87–95. EDN: QXDOMY doi: 10.18705/1607-419X-2022-28-1-87-95

[57] Moskalenko MI, Ponomarenko IV, Polonikov AV, et al. The role of obesity in the implementation of genetic predisposition to the development of essential hypertension in men. Obesity and Metabolism. 2019;16(4):66–72. EDN: XXYMMS doi: 10.14341/omet10053

[58] Москаленко М.И., Пономаренко И.В., Полоников А.В., и др. Роль ожирения в реализации генетической предрасположенности к развитию гипертонической болезни у мужчин // Ожирение и метаболизм. 2019. Т. 16, № 4. С. 66–72. EDN: XXYMMS doi: 10.14341/omet10053

[59] Myung J, Lee H, Kim TH, et al. Relationships between self-reported asthma and pulmonary function and various measures of obesity. J Asthma. 2018;55(7):741–749. doi: 10.1080/02770903.2017.1362701

[60] Myung J., Lee H., Kim T.H., Han E. Relationships between self-reported asthma and pulmonary function and various measures of obesity // J Asthma. 2018. Vol. 55, N 7. P. 741–749. doi: 10.1080/02770903.2017.1362701

[61] Lai L, Zhang T, Zeng X, et al. Association between physician-diagnosed asthma and weight status among chinese children: the roles of lifestyle factors. Int J Environ Res Public Health. 2020;17(5):1599. doi: 10.3390/ijerph17051599

[62] Lai L., Zhang T., Zeng X., et al. Association between physician-diagnosed asthma and weight status among chinese children: the roles of lifestyle factors // Int J Environ Res Public Health. 2020. Vol. 17, N 5. P. 1599. doi: 10.3390/ijerph17051599

[63] Chukaeva II, Klepikova MV, Orlova NV, Agaeva LM. Role of obesity in development of hypertension and efficiency of anorectic therapy. Medical Alphabet. 2018;1(12):37–39. EDN: UQLQSQ

[64] Чукаева И.И., Клепикова М.В., Орлова Н.В., Агаева Л.М. Роль ожирения в развитии артериальной гипертонии и эффективность анорексигенной терапии // Медицинский алфавит. 2018. Т. 1, № 12. С. 37–39. EDN: UQLQSQ

[65] Saliba LJ, Maffett S. Hypertensive heart disease and obesity: a review. Heart Fail Clin. 2019;15(4):509–517. doi: 10.1016/j.hfc.2019.06.003

[66] Saliba L.J., Maffett S. Hypertensive heart disease and obesity: a review // Heart Fail Clin. 2019. Vol. 15, N 4. P. 509–517. doi: 10.1016/j.hfc.2019.06.003

[67] Uksumenko AA, Antonyuk MV. Pathogenetic aspects of the phenotype of bronchial asthma associated with obesity. Bulletin Physiology and Pathology of Respiration. 2019;(71):112–119. EDN: YZXVKX doi: 10.12737/article_5c89ab4f8523c5.66345570

[68] Уксуменко А.А., Антонюк М.В. Патогенетические аспекты фенотипа бронхиальной астмы, ассоциированной с ожирением // Бюллетень физиологии и патологии дыхания. 2019. № 71. С. 112–119. EDN: YZXVKX doi: 10.12737/article_5c89ab4f8523c5.66345570

[69] Markova TN, Fomina DS, Kostenko AA, et al. Obesity and bronchial asthma: two diseases with common aspects of pathogenesis. The Russian Journal of Preventive Medicine. 2020;23(4):126–132. EDN: HIQYPP doi: 10.17116/profmed202023041126

[70] Маркова Т.Н., Фомина Д.С., Костенко А.А., Бобрикова Е.Н. Ожирение и бронхиальная астма: два заболевания с общими аспектами патогенеза // Профилактическая медицина. 2020. Т. 23, № 4. С. 126–132. EDN: HIQYPP doi: 10.17116/profmed202023041126

[71] Markova TN, Mishchenko NK, Petina DV. Adipocytokines: modern definition, classification and physiological role. Problems of Endocrinology. 2022;68(1):73–80. EDN: BWJQBG doi: 10.14341/probl12805

[72] Маркова Т.Н., Мищенко Н.К., Петина Д.В. Адипоцитокины: современный взгляд на дефиницию, классификацию и роль в организме // Проблемы эндокринологии. 2022. Т. 68, № 1. С. 73–80. EDN: BWJQBG doi: 10.14341/probl12805

[73] Zhang X, Zheng J, Zhang L, et al. Systemic inflammation mediates the detrimental effects of obesity on asthma control. Allergy Asthma Proc. 2018;39(1):43–50. doi: 10.2500/aap.2018.39.4096

[74] Zhang X., Zheng J., Zhang L., et al. Systemic inflammation mediates the detrimental effects of obesity on asthma control // Allergy Asthma Proc. 2018. Vol. 39, N 1. P. 43–50. doi: 10.2500/aap.2018.39.4096

[75] Chong L, Liu L, Zhu L, et al. Expression levels of predominant adipokines and activations of STAT3, STAT6 in an experimental mice model of obese asthma. Iran J Allergy Asthma Immunol. 2019;18(1):62–71.

[76] Chong L., Liu L., Zhu L., et al. Expression levels of predominant adipokines and activations of stat3, stat6 in an experimental mice model of obese asthma // Iran J Allergy Asthma Immunol. 2019. Vol. 18, N 1. P. 62–71.

[77] Watanabe K, Suzukawa M, Arakawa S, et al. Leptin enhances cytokine/chemokine production by normal lung fibroblasts by binding to leptin receptor. Allergol Int. 2019;68S:S3–S8. Corrected and republished from: Allergol Int. 2021;70(3):404. doi: 10.1016/j.alit.2019.04.002

[78] Watanabe K., Suzukawa M., Arakawa S., et al. Leptin enhances cytokine/chemokine production by normal lung fibroblasts by binding to leptin receptor // Allergol Int. 2019. Vol. 68S. P. S3–S8. Corrected and republished from: Allergol Int. 2021. Vol. 70. P. 404. doi: 10.1016/j.alit.2019.04.002

[79] Grasemann H, Holguin F. Oxidative stress and obesity-related asthma. Paediatr Respir Rev. 2021;37:18–21. doi: 10.1016/j.prrv.2020.05.004

[80] Grasemann H., Holguin F. Oxidative stress and obesity-related asthma // Paediatr Respir Rev. 2021. Vol. 37. P. 18–21. doi: 10.1016/j.prrv.2020.05.004

[81] Cunha CLPD. Obesity-Induced Hypertension. Arquivos Brasileiros de Cardiologia. 2023;120(7). (In Portuguese). doi: 10.36660/abc.20230391

[82] Cunha C.L.P.D. Hipertensão induzida pela obesidade // Arq Bras Cardiol. 2023. Vol. 120, N 7. P. e20230391. doi: 10.36660/abc.20230391

[83] Chumakova GA, Kuznetsova TY, Druzhilov MA, Veselovskaya NG. Obesity induced hypertension: the main pathophysiological mechanisms. Arterial’naya gipertenziya. 2021;27(2):260–268. EDN: OEYVXU doi:

[84] Чумакова Г.А., Кузнецова Т.Ю., Дружилов М.А., Веселовская Н.Г. Индуцированная ожирением артериальная гипертензия. Основные патофизиологические механизмы развития // Артериальная гипертензия. 2021. Т. 27, № 3. С. 260–268. EDN: OEYVXU doi:

[85] Molchanova OV. A modern view on the prevention and treatment of arterial hypertension in obesity. The Russian Journal of Preventive Medicine. 2021;24(6):97–103. EDN: DLFXPZ doi:

[86] Молчанова О.В. Современный взгляд на профилактику и лечение артериальной гипертонии при ожирении // Профилактическая медицина. 2021. Т. 24, № 6. С. 97–103. EDN: DLFXPZ doi:

[87] Andreeva GF, Smirnova MI, Gorbunov VM, et al. Seasonal indicators of blood pressure, data of asthma control questionnaires and quality of life in hypertensive patients with bronchial asthma. Rational Pharmacotherapy in Cardiology. 2019;15(6):831–839. EDN: CYULNE doi: 10.20996/1819-6446-2019-15-6-831-839

[88] Андреева Г.Ф., Смирнова М.И., Горбунов В.М., и др. Сезонные показатели артериального давления и данные опросников контроля астмы и качества жизни у больных артериальной гипертензией в сочетании с бронхиальной астмой // Рациональная фармакотерапия в кардиологии. 2019. Т. 15, № 6. С. 831–839. EDN: CYULNE doi: 10.20996/1819-6446-2019-15-6-831-839

[89] Partavi MS, Emel’janov AV, Sergeeva GR, Olimova FZ. Quality of life of patients with bronchial asthma and hypertension. In: 92nd All-Russian scientific and practical conference with international participation “Mechnikov readings — 2019»; 2019 Apr 24–25; Saint Petersburg. (In Russ). EDN: PBVFAH Available from: https://elibrary.ru/item.asp?id=38503581

[90] Партави М.С., Емельянов А.В., Сергеева Г.Р., Олимова Ф.З. Качество жизни больных с бронхиальной астмой и гипертонической болезнью. В кн.: 92 Всероссийская научно-практическая конференция с международным участием «Мечниковские чтения — 2019»; 24–25 апреля 2019 года; Санкт-Петербург. EDN: PBVFAH Режим доступа: https://elibrary.ru/item.asp?id=38503581

[91] Lin CH. Treatment of hypertension in patients with asthma. N Engl J Med. 2019;381(23):2278–2279. doi: 10.1056/NEJMc1913646

[92] Lin C.H. Treatment of hypertension in patients with asthma // N Engl J Med. 2019. Vol. 381, N 23. P. 2278–2279. doi: 10.1056/NEJMc1913646

[93] Kobalava ZhD, Konradi AO, Nedogoda SV, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3). EDN: TCRBRB doi: 10.15829/1560-4071-2020-3-3786

[94] Кобалава Ж.Д., Конради А.О., Недогода С.В., и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020 // Российский кардиологический журнал. 2020. Т. 25, № 3. EDN: TCRBRB doi: 10.15829/1560-4071-2020-3-3786

[95] Molostova TN. The use of b-blockers in patients with chronic obstructive pulmonary disease and asthma. Prakticheskaja pul’’monologija. 2018;(1):91–97. EDN: OVTGFJ

[96] Молостова Т.Н. Β-адреноблокаторы у больных хронической обструктивной болезнью легких и бронхиальной астмой // Практическая пульмонология. 2018. № 1. С. 91–97. EDN: OVTGFJ

RIGHTS & PERMISSIONS

Eco-Vector